Amgen, Onyx Pharmaceuticals Get Approval On Acquisition

Thousand Oaks-based Amgen and Onyx Pharmaceuticals said late Wednesday that the two have received early termination of the Hart-Scott-Rodino Antitrust waiting period for Amgen's acquisition of Onyx. Amgen announced on August 24th that it will pay $125 per share in cash, or roughly $10.4 billion, to acquire Onyx Pharmaceuticals, a South San Francisco-based developer of biopharmaceuticals to treat cancer.